Silexion selects CRO partner for upcoming KRAS cancer therapy trials

Silexion Therapeutics (NASDAQ:SLXN), a micro-cap biotech, has appointed AMS Advanced Medical Services as its contract research organization for upcoming Phase 2/3 clinical trials of its RNAi cancer therapy candidate, SIL204, targeting KRAS-driven solid tumors, with trials projected to commence in H1 2026. Despite promising preclinical data for SIL204, the company faces significant financial challenges, including rapid cash burn and a weak current ratio of 0.64, necessitating recent capital-raising efforts through an increased authorized share capital and warrant exercises to fund its development pipeline and operations.

Analysis

Silexion Therapeutics (NASDAQ:SLXN), a micro-cap biotech, is advancing its lead candidate, SIL204, by selecting AMS as its contract research organization for pivotal Phase 2/3 trials set to begin in H1 2026. This operational milestone is supported by promising preclinical data, where the RNAi therapy demonstrated up to 97% inhibition in pancreatic cancer cells and approximately 90% in colorectal cancer cells. However, this clinical potential is severely counterbalanced by significant financial distress. The company exhibits a weak financial health score, a rapid cash burn rate, and a current ratio of just 0.64, indicating substantial risk in meeting its short-term obligations. To address this, Silexion has undertaken several dilutive measures, including a 1-for-15 reverse stock split, an increase in authorized share capital, and the exercise of warrants at a reduced price to raise approximately $1.8 million. These actions underscore the company's urgent need for capital to fund its ambitious development timeline, creating a high-risk, high-reward scenario where promising science is pitted against precarious financial viability.

Key Decisions for Investors

• Investors should view SLXN as a highly speculative holding, where the primary risk is the company's ability to fund operations through its planned 2026 clinical trials, as evidenced by its rapid cash burn and low current ratio of 0.64.
• Monitor the upcoming earnings report on September 15, 2025, for explicit details on the company's funding strategy, as the pathway to financing the SIL204 program will be a critical determinant of future viability.
• Recognize that while the preclinical data for SIL204 is a significant scientific positive, recent corporate actions like the reverse split and warrant repricing are bearish financial signals, suggesting further shareholder dilution is highly probable to sustain operations.